Literature DB >> 20973119

Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

William C Floyd1, Gopal K Datta, Shinichi Imamura, Heidi M Kieler-Ferguson, Katherine Jerger, Andrew W Patterson, Megan E Fox, Francis C Szoka, Jean M J Fréchet, Jonathan A Ellman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20973119      PMCID： PMC3470805          DOI： 10.1002/cmdc.201000377

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  69 in total

1.  Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity.

Authors:  Axel Sandmann; Florenz Sasse; Rolf Müller
Journal:  Chem Biol       Date:  2004-08

2.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Authors:  Anil K Patri; Andrzej Myc; James Beals; Thommey P Thomas; Neil H Bander; James R Baker
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

3.  Discovery of 23 natural tubulysins from Angiococcus disciformis An d48 and Cystobacter SBCb004.

Authors:  Yi Chai; Dominik Pistorius; Angelika Ullrich; Kira J Weissman; Uli Kazmaier; Rolf Müller
Journal:  Chem Biol       Date:  2010-03-26

4.  Polymer-Based Therapeutics.

Authors:  Shuang Liu; Ronak Maheshwari; Kristi L Kiick
Journal:  Macromolecules       Date:  2009-01-13       Impact factor: 5.985

5.  Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel.

Authors:  Jayant J Khandare; Sreeja Jayant; Ajay Singh; Pooja Chandna; Yang Wang; Nicholi Vorsa; Tamara Minko
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

6.  Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives.

Authors:  Ranganathan Balasubramanian; Bhooma Raghavan; Jaeson C Steele; Dan L Sackett; Robert A Fecik
Journal:  Bioorg Med Chem Lett       Date:  2008-03-20       Impact factor: 2.823

Review 7.  Polymersome carriers: from self-assembly to siRNA and protein therapeutics.

Authors:  David A Christian; Shenshen Cai; Diana M Bowen; Younghoon Kim; J David Pajerowski; Dennis E Discher
Journal:  Eur J Pharm Biopharm       Date:  2008-10-17       Impact factor: 5.571

Review 8.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

9.  Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides.

Authors:  Iontcho R Vlahov; Yu Wang; Paul J Kleindl; Christopher P Leamon
Journal:  Bioorg Med Chem Lett       Date:  2008-07-15       Impact factor: 2.823

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701
View more
  1 in total

1.  Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Authors:  Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.